Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
- 21 January 2002
- reference entry
- review article
- Published by Wiley
- No. 2,p. CD001090
- https://doi.org/10.1002/14651858.cd001090
Abstract
Death from severe sepsis and septic shock is common, and researchers have explored whether antibodies to the endotoxins in some bacteria reduces mortality. This review summarises the effects of intravenous immunoglobulin (IVIG) in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. We searched the Cochrane Controlled Trials Register, MEDLINE 1966 to 2000, EMBASE 1988 to February 1999; we contacted investigators active in the field for unpublished data. Randomised trials comparing intravenous immunoglobulin (monoclonal or polyclonal) with placebo or no intervention, in patients with bacterial sepsis or septic shock. Inclusion criteria, trial quality assessment, and data abstraction were done in duplicate. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation. Twenty-seven out of 55 studies met our inclusion criteria. Pooled analysis of all types of IVIG preparations revealed a significant trend toward reduction of mortality (n= 8,856; RR=0.91; 95% CI 0.86 to 0.96). Overall mortality was reduced in patients who received polyclonal IVIG (n=492; RR=0.64; 95% CI 0.51 to 0.80). Mortality was not reduced among patients who received monoclonal antibodies such as anti-endotoxins (n=2,826 in 5 good-quality studies; RR=0.97; 95% CI 0.88 to 1.07) or anti-cytokines (n=4,318 in 4 good quality studies; RR=0.93; 95% CI 0.86 to 1.01). A few studies measured secondary outcomes (deaths from sepsis or length of hospitalisation) but no differences in the intervention and control groups were identified except among those who received polyclonal IVIG, where sepsis-related mortality was significantly reduced (n=161; RR=0.35; 95% CI 0.18 to 0.69). In our opinion, polyclonal IVIG significantly reduces mortality and can be used as an adjuvant treatment for sepsis and septic shock. Adjunctive therapy with monoclonal IVIGs remains experimental.Keywords
This publication has 83 references indexed in Scilit:
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Intensive Care Medicine, 2007
- IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*Critical Care Medicine, 2006
- Adverse Effects of Intravenous Immunoglobulin TherapyDrug Safety, 1999
- Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trialBurns, 1995
- Intravenous immune globulin therapy for early-onset sepsis in premature neonatesThe Journal of Pediatrics, 1992
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsisThe Journal of Pediatrics, 1992
- Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsisThe Journal of Pediatrics, 1991
- Safety of Intravenous Immunoglobulin Infusion in Neonates at Risk for SepsisAmerican Journal of Perinatology, 1990
- Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitisKlinische Wochenschrift, 1987